1/34
Looks like no tags are added yet.
Furosemide (Lasix)
Drug Class: Loop diuretic. Clinical Indication: Fluid overload, edema, and blood pressure reduction in advanced kidney disease. Key Monitoring: Serum potassium (hypokalemia), serum creatinine/eGFR, and ototoxicity/hearing loss in high-risk patients.
Amlodipine (Norvasc)
Drug Class: Long-acting dihydropyridine calcium channel blocker (DHP-CCB). Clinical Indication: First-line agent for uncomplicated hypertension. Key Adverse Effect: Dose-dependent lower extremity peripheral edema (vasodilatory, not fluid overload).
Metoprolol Tartrate (Lopressor)
Drug Class: Second-generation β1​-selective adrenergic antagonist. Formulation/Dosing: Regular/immediate-release requiring twice-daily (BID) administration.
Metoprolol Succinate (Toprol XL)
Drug Class: Second-generation β1​-selective adrenergic antagonist. Formulation/Dosing: Extended-release (ER) formulation providing once-daily (QD) coverage for hypertension and heart failure.
Carvedilol (Coreg)
Drug Class: Third-generation non-selective β-blocker with α1​-adrenoceptor blocking properties. Clinical Indication: Preferred in heart failure and post-myocardial infarction (MI).
Diltiazem (Cardizem)
Drug Class: Non-dihydropyridine calcium channel blocker (non-DHP-CCB). Clinical Indication: Ventricular rate control in atrial fibrillation and angina; excluded from first-line status for uncomplicated hypertension.
Losartan (Cozaar)
Drug Class: Angiotensin II receptor blocker (ARB). Clinical Indication: First-line for uncomplicated hypertension and preferred in diabetic nephropathy/albuminuria (≥30mg/g); alternative for patients with ACEI-induced cough.
Valsartan (Diovan)
Drug Class: Angiotensin II receptor blocker (ARB). Clinical Indication: First-line for uncomplicated hypertension, chronic coronary disease, and heart failure.
Triamterene / Hydrochlorothiazide (Dyazide)
Drug Class: Combination potassium-sparing diuretic and thiazide diuretic. Mechanism: Offsets thiazide-induced urinary potassium wasting while providing synergistic natriuresis.
Valsartan / Sacubitril (Entresto)
Drug Class: Angiotensin receptor-neprilysin inhibitor (ARNI). Clinical Indication: Heart failure with reduced ejection fraction (HFrEF); requires a 36-hour washout period if transitioning from an ACEI to prevent severe angioedema.
Dapagliflozin (Farxiga)
Drug Class: Sodium-glucose cotransporter 2 (SGLT2) inhibitor. Clinical Indication: Heart failure, type 2 diabetes, and chronic kidney disease (CKD). Key Monitoring: Baseline and routine SCr/eGFR and serum potassium.
Empagliflozin (Jardiance)
Drug Class: Sodium-glucose cotransporter 2 (SGLT2) inhibitor. Clinical Indication: Type 2 diabetes and heart failure. Key Monitoring: Renal function (eGFR) and volume status.
Blood Pressure Staging: Normal Blood Pressure
Systolic blood pressure (SBP) <120mmHg and diastolic blood pressure (DBP) <80mmHg.
Blood Pressure Staging: Stage 1 Hypertension
SBP 130–139mmHg or DBP 80–89mmHg. Diagnosis requires confirmed average readings across at least 2 separate clinical encounters.
Blood Pressure Staging: Stage 2 Hypertension
SBP≥140mmHg or DBP≥90mmHg.
Blood Pressure Staging: Discordant Category Rule
When systolic and diastolic values fall into different diagnostic categories, the patient is classified definitively by the higher, more severe stage (e.g., 135/94mmHg is Stage 2 based on the DBP).
Therapeutic Blood Pressure Target (2025 Guidelines)
Primary goal for most treated patients is <130/80mmHg. An intensive goal of SBP<120mmHg can be considered for select high-risk patients if clinically tolerated.
First-Line Antihypertensive Classes for Uncomplicated Hypertension
1. Thiazide-type/thiazide-like diuretics, 2. Long-acting dihydropyridine calcium channel blockers (DHP-CCBs), 3. Angiotensin-converting enzyme inhibitors (ACEIs), 4. Angiotensin receptor blockers (ARBs). Note: β-blockers and non-DHP-CCBs are not first-line for uncomplicated disease.
Pharmacotherapy Initiation: Stage 1 vs. Stage 2 Hypertension
Stage 2 (≥140/90mmHg): Start immediately with 2 first-line agents from different classes (single-pill fixed-dose combination preferred). Stage 1 (130–139/80–89mmHg): Start monotherapy if high-risk (clinical CVD, diabetes, CKD, or PREVENT-CVD 10-year risk≥7.5%); initiate 3 to 6months of lifestyle modifications if low-risk (<7.5%).
Contraindication: Dual RAAS Inhibition
Simultaneous co-administration of an ACEI with an ARB or direct renin inhibitor is strictly contraindicated due to increased risk of hyperkalemia, acute kidney injury, and profound hypotension without added clinical benefit.
Preferred Antihypertensives: Diabetes Mellitus with CKD / Albuminuria
ACEIs or ARBs are preferred first-line when diabetes presents with eGFR<60mL/min/1.73 m2 or persistent albuminuria (urine albumin-to-creatinine ratio≥30mg/g) due to renal protective benefits.
Preferred Antihypertensives: Chronic Coronary Disease / Post-MI
β-blockers, ACEIs, and ARBs are elevated to first-line status due to proven reductions in cardiovascular mortality and re-infarction risk.
Preferred Antihypertensives: Atrial Fibrillation
β-blockers are preferred initial agents to provide ventricular rate control while concurrently decreasing systemic blood pressure.
Preferred Antihypertensives: Prior Stroke / Cerebrovascular Disease
A thiazide-type diuretic, an ACEI, or an ARB is preferred for secondary stroke prevention; calcium channel blockers are de-emphasized.
Hypertension in Pregnancy: Preferred Outpatient Medications
Oral labetalol and extended-release (ER) nifedipine are the primary first-line therapies; oral methyldopa is a secondary alternative.
Hypertension in Pregnancy: Acute Inpatient Emergency Management
Intravenous (IV) labetalol, intravenous (IV) hydralazine, and immediate-release oral nifedipine.
Hypertension in Pregnancy: Absolute Contraindications
All RAAS inhibitors (ACEIs, ARBs, direct renin inhibitors), mineralocorticoid receptor antagonists (MRAs: spironolactone, eplerenone), atenolol (associated with severe fetal growth restriction), and sodium nitroprusside (fetal cyanide poisoning).
Definition of Resistant Hypertension
Blood pressure uncontrolled (≥130/80mmHg) despite verified adherence to maximally tolerated doses of 3 complementary antihypertensive classes (including a diuretic), OR blood pressure controlled (<130/80mmHg) requiring ≥4 distinct antihypertensive medications.
Pseudoresistant Hypertension Causes
1. Medication non-adherence (most common cause), 2. Incorrect blood pressure measurement technique (improper cuff size, talking, lack of back/arm support), 3. White Coat effect. Pseudoresistance must be ruled out before intensifying pharmacotherapy.
Interfering Substances that Elevate Blood Pressure
NSAIDs (blunt prostaglandin synthesis and diuretic efficacy), oral/topical nasal decongestants (pseudoephedrine, phenylephrine, oxymetazoline), systemic corticosteroids, stimulants, caffeine, nicotine, and heavy alcohol intake.
Stepwise Management of Resistant Hypertension
Step 1: Maximize diuretic therapy (switch HCTZ to longer-acting chlorthalidone or indapamide; switch to loop diuretics in advanced CKD). Step 2: Add an MRA (spironolactone or eplerenone) after verifying adequate eGFR and normal serum potassium. Step 3: Add complementary agents (β-blockers, non-DHP-CCBs, or central α2​-agonists like clonidine). Step 4: Add direct vasodilators (hydralazine, minoxidil, aprocitentan).
Chlorthalidone vs. Hydrochlorothiazide (HCTZ)
Chlorthalidone has a significantly longer elimination half-life and greater milligram-for-milligram potency compared to hydrochlorothiazide, making it the preferred substitution for inadequate blood pressure response.
Key Monitoring Parameters: Thiazide Diuretics
Blood pressure efficacy, serum potassium (risk of hypokalemia), serum sodium (hyponatremia), serum calcium (hypercalcemia), blood glucose (hyperglycemia), uric acid (hyperuricemia / gout flares), and SCr/eGFR.
Key Monitoring Parameters: ACE Inhibitors and ARBs
Blood pressure efficacy, serum potassium (risk of hyperkalemia), SCr/eGFR (acute kidney injury), angioedema risk, and persistent dry non-productive cough (ACEI-specific, mediated by bradykinin; managed by switching to an ARB).
Clinical Pearl: Regimen Simplification and Medication Timing
Switch captopril (BID/TID) to once-daily lisinopril; switch metoprolol tartrate (BID) to once-daily metoprolol succinate; administer potent loop diuretics (e.g., furosemide) in the morning or after breakfast rather than in the evening (8:00PM) to prevent nocturia and sleep fragmentation.